Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of November 2025, with a specific reporting date of November 13, 2025. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| 2025-11-11 | Ordinary Shares (31 1/2 pence each) | £18.1420 | 90 Shares (Aggregated) | London Stock Exchange (XLON) |
Note: The total volume of 90 shares is derived from the sum of individual transactions listed below. All transactions were acquisitions under the Company's Share Reward Plan.
Material Changes and Transaction Details
The filing reports initial notifications of share acquisitions by eight senior executives on November 11, 2025. There are no material changes to the company's financial position reported in this document.
- Emma Walmsley (CEO): Acquired 14 shares (7 partnership, 7 matching).
- Julie Brown (CFO): Acquired 14 shares (7 partnership, 7 matching).
- James Ford (SVP, Legal and Compliance): Acquired 14 shares (7 partnership, 7 matching).
- Sally Jackson (SVP, Global Communications): Acquired 14 shares (7 partnership, 7 matching).
- David Redfern (President, Corporate Development): Acquired 12 shares (6 partnership, 6 matching).
- Regis Simard (President, Global Supply Chain): Acquired 14 shares (7 partnership, 7 matching).
- Philip Thomson (President, Global Affairs): Acquired 14 shares (7 partnership, 7 matching).
- Deborah Waterhouse (CEO, ViiV Healthcare): Acquired 14 shares (7 partnership, 7 matching).
- Victoria Whyte (SVP & Company Secretary): Acquired 14 shares (7 partnership, 7 matching).
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of insider share purchases.
Key Facts for Investor Verification
- Insider Sentiment: Multiple C-suite executives and senior leaders simultaneously acquired shares, indicating alignment with the Share Reward Plan.
- Transaction Price: All shares were acquired at a uniform price of £18.1420.
- Transaction Nature: All purchases were structured as "partnership shares" and "matching shares," typical of employee benefit schemes rather than open market speculation.
- Volume: The total number of shares acquired by these executives in this specific batch is minimal (90 shares total), suggesting these are likely vesting events or small matching contributions rather than significant capital deployment.